Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
Yang, Y; Xu, JH; Xu, J; Li, XF; Hu, JK; Li, XP; Zhang, X; He, DY; Bao, CD; Li, ZJ; Wang, GC; Zerbini, CAF; Spindler, AJ; Kannowski, CL; Wu, HJ; Ji, F; Zhan, LJ; Liu, MR; Li, ZG
Yang, Y (corresponding author), Peking Univ, Peoples Hosp, Inst Rheumatol & Immunol, 11 Xizhimen South St, Beijing 100029, Peoples R China.; Li, ZG (corresponding author), Peking Univ, Peoples Hosp, Dept Rheumatol & Immun, Ctr Clin Immunol, Beijing, Peoples R China.; Li, ZG (corresponding author), Peking Univ, Inst Rheumatol & Immunol, Med Sch, 11 Xizhimen South St, Beijing 100029, Peoples R China.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ():
